CONCLUSIONS
schizophrenia
The results of this OLE study support the long-term safety and efficacy of PP6M administration up to 24 months under circumstances similar to real-world conditions in participants with schizophrenia. Clinical improvements demonstrated in the DB study were maintained in this OLE study with stable scores of PANSS total, CGI-S, and PSP scales and very few relapses. Despite the larger volume of PP6M doses administered in the gluteal muscle compared with PP1M or PP3M, no new safety concerns were identified over the 2-year OLE period.